Brokerage firm Citigroup Downgrades its rating on Becton Dickinson and Co(NYSE:BDX). In a research note issued to the investors, the brokerage major Lowers the price-target to $165.00 per share. The shares have been rated Sell. Previously, the analysts had a Neutral rating on the shares. The rating by Citigroup was issued on Sep 23, 2016.
In a different note, On Aug 5, 2016, UBS said it Maintains its rating on Becton Dickinson and Co. In the research note, the firm Raises the price-target to $182.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 28, 2016, Jefferies said it Maintains its rating on Becton Dickinson and Co. In the research note, the firm Raises the price-target to $190.00 per share. The shares have been rated ‘Buy’ by the firm.
Becton Dickinson and Co (BDX) made into the market gainers list on Tuesdays trading session with the shares advancing 1.11% or 1.96 points. Due to strong positive momentum, the stock ended at $178.97, which is also near the day’s high of $178.99. The stock began the session at $177.33 and the volume stood at 6,75,452 shares. The 52-week high of the shares is $181.755 and the 52 week low is $128.87. The company has a current market capitalization of $38,107 M and it has 21,29,25,840 shares in outstanding.
Becton Dickinson and Co(BDX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $3.20B. Analysts had an estimated revenue of $3.22B. Earnings per share were $2.35. Analysts had estimated an EPS of $2.21.
Several Insider Transactions has been reported to the SEC. On Sep 7, 2016, Linda M Tharby (Executive Vice President) sold 11,704 shares at $177.34 per share price.Also, On Aug 12, 2016, Gary M Cohen (Executive Vice President) sold 29,367 shares at $176.81 per share price.On Jun 14, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,931 shares at $169.87 per share price, according to the Form-4 filing with the securities and exchange commission.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.